Avalyn Pharma Acquisition | Healthcare Deal in NY

Avalyn Pharma has completed the acquisition of Avalyn Pharma, a pharmacy business in New York, for $300 million. Avalyn Pharma is a clinical-stage biopharmaceutical company focused on inhaled therapies for serious, rare respiratory diseases, including pulmonary fibrosis. The company’s inhaled formulations are designed to deliver antifibrotic medicines directly to the lungs, supporting a growth strategy in healthcare deals NY and NY acquisitions. The announced upsized initial public offering priced 16,666,667 shares at $18.00 per share, with an underwriters’ option for 2,500,000 additional shares, expected to begin trading on Nasdaq Global Select Market under AVLN on April 30, 2026 and close May 1, 2026.